LALINDEN ADVISORS LP

Institutional investor · Portfolio as of Q4 2025

Top Holdings472 positions

Checking export access…
Activity:
284.2M$807.1M5.0%——
12 qtrssince 2023-Q1
Increased
63
239.9M$644M4.0%———
New
87
93.3M$496M3.1%———
Increased
60
130.4M$350.9M2.2%———
New
80
89.7M$333M2.1%———
Increased
56
314.2M$289.5M1.8%———
New
71
255.7M$283.4M1.7%———
New
70
222.4M$281.2M1.7%———
Increased
64
??MKS INC.
Bond
213.1M$272.5M1.7%———
Increased
50
??LI AUTO INCDelisted
Bond
261.7M$263.6M1.6%——
15 qtrssince 2022-Q2
Decreased
0
249.4M$251.1M1.5%———
Decreased
0
238.1M$244.9M1.5%——
8 qtrssince 2024-Q1
Decreased
0
214M$241M1.5%———
Increased
58
187.1M$236.8M1.5%———
New
70
175.5M$234M1.4%———
Decreased
0
137.6M$229.1M1.4%———
Increased
48
82.3M$226.5M1.4%———
Increased
49
154.3M$218.6M1.3%———
Increased
61
209.5M$217.2M1.3%———
New
70
139.4M$216.9M1.3%———
Decreased
0
$16.2B
AUM
472
Positions
Q4 2025
Filing
HI score · 2.0/5
Quarterly 13F Value Change
+14%Q2'24$12B+1%Q4'24$12.1B+22%Q1'25$14.7B+10%Q2'25$16.3B-8%Q3'25$15B+8%Q4'25$16.2B
Activity profile
$ moved · Q4'25
New39%Increased18%Decreased18%Exited25%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.1 quarters
<1Q28%1-4Q48%1-2Y11%2Y+13%

LINDEN ADVISORS LP manages $16.2B across 472 positions as of Q4 2025. Top holdings: LUMENTUM HLDGS INC (5.0%), CENTRUS ENERGY CORP (4.0%), LUMENTUM HLDGS INC (3.1%). Fund DNA: Diversified Scout. HoldingsIntel Score: 2/5.0.

Q4 2025 Summary

Active quarter - 137 new positions, 72 exits, 50 increased. No standout high-conviction moves this quarter. Portfolio: $16.2B across 472 positions.

Top holdings by portfolio weight

Total AUM$16B
LUMENTUM HLD4.97%
CENTRUS ENER3.96%
LUMENTUM HLD3.05%
APPLIED DIGI2.16%
LUMENTUM HOL2.05%
BILL HOLDING1.78%
AFFIRM HLDGS1.74%
STRATEGY INC1.73%
MKS INC.1.68%
LI AUTO INC1.62%
Other1.55%

Portfolio allocation by GICS sector

Sectors5
Financial Services64.74%
Unknown32.46%
Healthcare2.43%
Communication Services0.21%
Utilities0.16%

Behavioral investing profile

Checking access…
Diversified Scout
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(2.0 / 5.0)
Holdings P&L57
Conviction31
Concentration37
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
BR10806XAD4BRIDGEBIO PHARMA INC
Q4 2024 → Q2 2026+151.4M shares+$192.5M
7Q
VI928298AR9VISHAY INTERTECHNOLOGY INC
Q4 2024 → Q2 2026+353.9M shares+$770.5M
4Q
CO19459JAC8COLLEGIUM PHARMACEUTICAL INC
Q3 2025 → Q2 2026+26.6M shares+$50.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used